GlassScriptPhysician profile
Ashley Mckillop
NPI 1851885446
$14,397.42
in general payments reported to CMS, 2019-2025
36 companies · $3,160 in 2025
The $3,160 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,932 · 2022: $2,151 · 2023: $3,223 · 2024: $3,931 · 2025: $3,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,314.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,077.93 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,238.96 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,172.36 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $892.94 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $820.75 | 2021-2025 | |
| Madrigal Pharmaceuticals | $575.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $549.71 | 2022-2025 | |
| Celgene Corporation | $413.30 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $353.84 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $318.76 | 2021-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $285.76 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $279.79 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $250.22 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $213.03 | 2023-2025 | Ibsrela |
| Pfizer INC. | $159.60 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $100.08 | 2022 | |
| Ironwood Pharmaceuticals, INC | $80.55 | 2023-2024 | Linzess |
| Braintree Laboratories, INC. | $75.90 | 2023-2024 | Suflave |
| Aimmune Therapeutics, INC. | $57.42 | 2025 | Zenpep |
| Organon LLC | $51.20 | 2023-2025 | Renflexis, Hadlima |
| Sandoz INC. | $45.68 | 2023-2025 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.66 | 2023 | Cyltezo |
| Echosens North America, INC. | $40.30 | 2024 | Fibroscan |
| Intercept Pharmaceuticals, INC. | $39.67 | 2022-2025 | |
| Medtronic, INC. | $34.42 | 2024 | Gi Genius |
| Merck Sharp & Dohme LLC | $31.41 | 2023 | Dificid |
| Fresenius Kabi USA, LLC | $30.41 | 2023 | Idacio |
| Celltrion USA INC. | $30.20 | 2024 | Vegzelma |
| Orphalan INC | $27.79 | 2024 | Cuvrior |
| Mylan Institutional INC. | $20.95 | 2023 | |
| Alfasigma USA, INC. | $16.76 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.01 | 2023 | Rebyota |
| Mirum Pharmaceuticals, INC. | $14.94 | 2025 | Livmarli |
| Curonix LLC | $14.49 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nestle Healthcare Nutrition INC. | $12.40 | 2022 | |
| Redhill Biopharma INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mckillop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.